Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities

European Journal of Endocrinology

Volumn 170, Issue 1, 2014, Pages 39-48

  Olarescu, Nicoleta C ^a,d   Ueland, Thor ^b   Godang, Kristin ^a   Lindberg Larsen, Rune ^c   Jørgensen, Jens Otto L ^c   Bollerslev, Jens ^a,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; GLUCOSE; GROWTH HORMONE; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; THIOREDOXIN; VASCULOTROPIN A;

ACROMEGALY; ADIPOCYTE; ADIPONECTIN GENE; ADULT; ARTICLE; BODY FAT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; GENE; GENE EXPRESSION; GLUCOSE METABOLISM; HIGH MOLECULAR WEIGHT ADIPONECTIN GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN RESISTANCE; LEAN BODY WEIGHT; MALE; MCP1 GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSSPHENOIDAL SURGERY; TREATMENT RESPONSE; TRX GENE; VEGF A GENE;

ACROMEGALY; ADIPOSITY; ADULT; CELLS, CULTURED; CHEMOKINE CCL2; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMAN GROWTH HORMONE; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; OCTREOTIDE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SOMATOSTATIN; SUBCUTANEOUS FAT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84890538134     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0523     Document Type: Article

References (39)

1. Melmed S. Medical progress: acromegaly. New England Journal of Medicine 2006 355 2558-2573. (doi:10.1056/NEJMra062453)
2. Moller N & Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews 2009 30 152-177. (doi:10.1210/er.2008-0027)
3. Olarescu NC, Ueland T, Lekva T, Dahl TB, Halvorsen B, Aukrust P & Bollerslev J. Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly. Journal of Clinical Endocrinology and Metabolism 2012 97 1355-1362. (doi:10.1210/jc.2011- 2417)
4. Yeop HC, Kargi AY, Omer M, Chan CK, Wabitsch M, O'Brien KD, Wight TN & Chait A. Differential effect of saturated and unsaturated free fatty acids on the generation of monocyte adhesion and chemotactic factors by adipocytes: dissociation of adipocyte hypertrophy from inflammation. Diabetes 2010 59 386-396. (doi:10.2337/db09-0925)
5. Samuel VT, Petersen KF & Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010 375 2267-2277. (doi:10.1016/S0140-6736(10)60408-4)
6. del Rincon JP, Iida K, Gaylinn BD, McCurdy CE, Leitner JW, Barbour LA, Kopchick JJ, Friedman JE, Draznin B & Thorner MO. Growth hormone regulation of p85a expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes 2007 56 1638-1646. (doi:10.2337/db06-0299)
7. Takano A, Haruta T, Iwata M, Usui I, Uno T, Kawahara J, Ueno E, Sasaoka T & Kobayashi M. Growth hormone induces cellular insulin resistance by uncoupling phosphatidylinositol 3-kinase and its down-stream signals in 3T3-L1 adipocytes. Diabetes 2001 50 1891-1900. (doi:10.2337/diabetes.50.8.1891)
8. Krusenstjerna-Hafstrom T, Madsen M, Vendelbo MH, Pedersen SB, Christiansen JS, Moller N, Jessen N & Jorgensen JO. Insulin and GH signaling in human skeletal muscle in vivo following exogenous GH exposure: impact of an oral glucose load. PLoS ONE 2011 6 e19392. (doi:10.1371/journal.pone.0019392)
9. Wabitsch M, Hauner H, Heinze E & Teller WM. The role of growth hormone/insulin-like growth factors in adipocyte differentiation. Metabolism 1995 44 45-49. (doi:10.1016/0026-0495(95)90220-1)
10. Olefsky JM & Glass CK. Macrophages, inflammation, and insulin resistance. Annual Review of Physiology 2010 72 219-246. (doi:10.1146/annurev- physiol-021909-135846)
11. Glass CK & Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metabolism 2012 15 635-645. (doi:10.1016/j.cmet.2012.04.001)
12. Tilg H & Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews. Immunology 2006 6 772-783. (doi:10.1038/nri1937)
13. Sherlock M, Woods C & Sheppard MC. Medical therapy in acromegaly. Nature Reviews. Endocrinology 2011 7 291-300. (doi:10.1038/nrendo.2011.42)
14. Krusenstjerna-Hafstrom T, Vestergaard ET, Buhl M, Nielsen R, Clasen BF, Nielsen S, Moller N, Pedersen SB & Jorgensen JO. Acute peripheral metabolic effects of intraarterial leg infusion of somatostatin in healthy young men. Journal of Clinical Endocrinology and Metabolism 2011 96 2581-2589. (doi:10.1210/jc.2011-0592)
15. Moller N, Bagger JP, Schmitz O, Jorgensen JO, Ovesen P, Moller J, Alberti KG & Orskov H. Somatostatin enhances insulin-stimulated glucose uptake in the perfused human forearm. Journal of Clinical Endocrinology and Metabolism 1995 80 1789-1793. (doi:10.1210/jc.80.6.1789)
16. Alberti KG, Christensen NJ, Christensen SE, Hansen AP, Iversen J, Lundbaek K, Seyer-Hansen K & Orskov H. Inhibition of insulin secretion by somatostatin. Lancet 1973 2 1299-1301. (doi:10.1016/S0140-6736(73)92873-0)
17. Pokrajac A, Frystyk J, Flyvbjerg A & Trainer PJ. Pituitary- independent effect of octreotide on IGF1 generation. European Journal of Endocrinology 2009 160 543-548. (doi:10.1530/EJE-08-0822)
18. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP & Trainer PJ. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. European Journal of Endocrinology 2003 149 521-527. (doi:10.1530/eje.0.1490521)
19. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, VonWerder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529. (doi:10.1210/jc.85.2.526)
20. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL & Bollerslev J. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. Journal of Clinical Endocrinology and Metabolism 2008 93 2984-2990. (doi:10.1210/jc.2008-0315)
21. Lindberg-Larsen R, Moller N, Schmitz O, Nielsen S, Andersen M, Orskov H & Jorgensen JO. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2007 92 1724-1728. (doi:10.1210/jc.2006-2276)
22. Ueland T, Fougner SL, Godang K, Schreiner T & Bollerslev J. Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. European Journal of Endocrinology 2006 155 709-715. (doi:10.1530/eje.1.02285)
23. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C & Orskov H. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Journal of Clinical Endocrinology and Metabolism 2005 90 5627-5631. (doi:10.1210/jc.2005-0531)
24. Wallace TM, Levy JC & Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004 27 1487-1495. (doi:10.2337/diacare.27.6.1487)
25. Hursting SD & Hursting MJ. Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 1766-1770. (doi:10.1161/ATVBAHA.111.241927)
26. Dahlman I, Kaaman M, Olsson T, Tan GD, Bickerton AS, Wahlen K, Andersson J, Nordstrom EA, Blomqvist L, Sjogren A et al. A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects. Journal of Clinical Endocrinology and Metabolism 2005 90 5834-5840. (doi:10.1210/jc.2005-0369)
27. Agudo J, Ayuso E, Jimenez V, Casellas A, Mallol C, Salavert A, Tafuro S, Obach M, Ruzo A, Moya M et al. Vascular endothelial growth factor-mediated islet hypervascularization and inflammation contribute to progressive reduction of β-cell mass. Diabetes 2012 61 2851-2861. (doi:10.2337/db12-0134)
28. Tinahones FJ, Coin-Araguez L, Mayas MD, Garcia-Fuentes E, Hurtado-Del-Pozo C, Vendrell J, Cardona F, Calvo RM, Obregon MJ & El Bekay R. Obesity-associated insulin resistance is correlated to adipose tissue vascular endothelial growth factors and metalloproteinase levels. BMC Physiology 2012 12 4. (doi:10.1186/1472-6793-12-4)
29. Bays HE. Adiposopathy is "sick fat" a cardiovascular disease? Journal of the American College of Cardiology 2011 57 2461-2473. (doi:10.1016/j.jacc.2011.02.038)
30. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A et al . Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clinical Endocrinology 2003 59 492-499. (doi:10.1046/j.1365-2265.2003.01876.x)
31. Tzanela M, Vassiliadi DA, Gavalas N, Szabo A, Margelou E, Valatsou A & Vassilopoulos C. Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clinical Endocrinology 2011 75 96-102. (doi:10.1111/j.1365-2265.2011.03996.x)
32. Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F & Schopohl J. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. European Journal of Endocrinology 2006 155 73-78. (doi:10.1530/eje.1.02185)
33. Naraev BG, Strosberg JR & Halfdanarson TR. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology 2012 83 117-127. (doi:10.1159/000339539)
34. Zschauer TC, Matsushima S, Altschmied J, Shao D, Sadoshima J & Haendeler J. Interacting with thioredoxin-1 - disease or no disease? Antioxidants & Redox Signaling 2013 18 1053-1062. (doi:10.1089/ars.2012. 4822)
35. Pisprasert V, Ingram KH, Lopez-Davila MF, Munoz AJ & Garvey WT. Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans. Diabetes Care 2013 36 845-853. (doi:10.2337/dc12-0840)
36. List EO, Sackmann-Sala L, Berryman DE, Funk K, Kelder B, Gosney ES, Okada S, Ding J, Cruz-Topete D & Kopchick JJ. Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHRK/K) mouse. Endocrine Reviews 2010 32 356-386. (doi:10.1210/er.2010-0009)
37. Liu M, Xiang R, Wilk SA, Zhang N, Sloane LB, Azarnoush K, Zhou L, Chen H, Xiang G, Walter CA et al . Fat-specific DsbA-L overexpression promotes adiponectin multimerization and protects mice from diet-induced obesity and insulin resistance. Diabetes 2012 61 2776-2786. (doi:10.2337/db12-0169)
38. Zhu N, Pankow JS, Ballantyne CM, Couper D, Hoogeveen RC, Pereira M, Duncan BB & Schmidt MI. High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. Journal of Clinical Endocrinology and Metabolism 2010 95 5097-5104. (doi:10.1210/jc.2010-0716)
39. Ho DY, Cook NR, Britton KA, Kim E, Creager MA, Ridker PM & Pradhan AD. High-molecular-weight and total adiponectin levels and incident symptomatic peripheral artery disease in women: a prospective investigation. Circulation 2011 124 2303-2311. (doi:10.1161/CIRCULATIONAHA.111.045187)